IOVA (Iovance Biotherapeutics) Other Current Payables: $0.0 Mil (As of Mar. 2026)


IOVA Iovance Biotherapeutics Inc IOVA
44 GF Score
Price $3.97
GF Value $18.91
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Iovance Biotherapeutics Other Current Payables?

Iovance Biotherapeutics IOVA -4.57% 44 Other Current Payables is $0.0 Mil as of Mar. 2026. GuruFocus rates IOVA with a GF Score™ of 44/100 and a GF Value™ of $18.91 (Possible Value Trap). The stock has 2 warning signs investors should review.

Iovance Biotherapeutics's Other Current Payables for the quarter that ended in Mar. 2026 was $0.0 Mil.

Iovance Biotherapeutics Other Current Payables Related Terms

Iovance Biotherapeutics Other Current Payables Historical Data

* Premium members only.

The historical data trend for Iovance Biotherapeutics's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Iovance Biotherapeutics Other Current Payables Chart

Iovance Biotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Iovance Biotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
IOVA
44GF Score
Iovance Biotherapeutics Inc IOVA
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Iovance Biotherapeutics Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of $0.0 Mil mean?
Iovance Biotherapeutics (IOVA) has a Other Current Payables of $0.0 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Iovance Biotherapeutics and its competitors.
Is Iovance Biotherapeutics' Other Current Payables too high?
Iovance Biotherapeutics' current Other Current Payables is $0.0 Mil. Overall, Iovance Biotherapeutics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Iovance Biotherapeutics' Other Current Payables compare to SNDX and GLUE?
Iovance Biotherapeutics' Other Current Payables of $0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Iovance Biotherapeutics and its competitors. Iovance Biotherapeutics's current Other Current Payables is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iovance Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Iovance Biotherapeutics (IOVA) is currently considered Possible Value Trap. The stock's GF Value™ is $18.91, compared to a current price of $3.97 — trading 79% below its estimated fair value. The current Other Current Payables is $0.0 Mil. Iovance Biotherapeutics' overall GF Score™ is 44/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Iovance Biotherapeutics (IOVA), the current Other Current Payables is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Iovance Biotherapeutics (IOVA) Overvalued in 2026?

Based on GuruFocus' analysis, Iovance Biotherapeutics stock appears to be undervalued. The current stock price of $3.97 is trading 79% below its estimated GF Value™ of $18.91. GuruFocus considers Iovance Biotherapeutics to be Possible Value Trap.

Key valuation signals for IOVA:

  • Other Current Payables: $0.0 Mil
  • GF Value™: $18.91 vs. price of $3.97 (79% below fair value)
  • GF Score™: 44/100 with 2 warning signs

No single metric tells the full story. See the IOVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Iovance Biotherapeutics Business Description

Address 825 Industrial Road, Suite 100, San Carlos, CA, USA, 94070
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
44GF Score

Get the complete analysis for IOVA

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.97
Price
$18.91
GF Value